Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 10, Issue 4, 2012, Pages 239-245

  Pond, Gregory R ^a   Berry, William R ^b   Galsky, Matthew D ^c   Wood, Brian A ^d   Leopold, Lance ^d   Sonpavde, Guru ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b Raleigh Hematology Oncology Associates   (United States)

^c Mount Sinai Tisch Cancer Institute   (United States)

^d Ascenta Therapeutics   (United States)

^e Department of Pharmacology and Toxicology and Mass Spectrometry Core Facility   (United States)

Author keywords

Docetaxel; Metastatic castration resistant prostate cancer; Neutropenia; Pharmacodynamic marker

Indexed keywords

DOCETAXEL; ISOSORBIDE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANEMIA; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; FUNCTIONAL STATUS; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VISCERAL METASTASIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; GOSSYPOL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM METASTASIS; NEUTROPENIA; PREDNISONE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84868593906     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.06.004     Document Type: Article

References (32)

1. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
2. D.P. Petrylak, C.M. Tangen, M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
3. S.D. Baker, A. Sparreboom, J. Verweij Clinical pharmacokinetics of docetaxel: recent developments Clin Pharmacokinet 45 2006 235 252
4. R. Bruno, D. Hille, A. Riva Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer J Clin Oncol 16 1998 187 196
5. R. Bruno, R. Olivares, J. Berille Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel Clin Cancer Res 9 2003 1077 1082
6. A. Hussain, N. Dawson, P. Amin Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer J Clin Oncol 23 2005 2789 2796
7. D. Rathkopf, M.A. Carducci, M.J. Morris Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer J Clin Oncol 26 2008 2959 2965
8. R.M. Franke, M.A. Carducci, M.A. Rudek Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer J Clin Oncol 28 2010 4562 4567
9. A.J. Armstrong, I.F. Tannock, R. de Wit The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer 46 2010 517 525
10. J. O'Quigley, P. Flandre Quantification of the prentice criteria for surrogate endpoints Biometrics 62 2006 297 300
11. G. Sonpavde, V. Matveev, J.M. Burke Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer Ann Oncol 23 2011 1803 1808
12. A.J. Armstrong, E. Garrett-Mayer, Y.C. Ou Yang Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol 25 2007 3965 3970
13. D.P. Petrylak, D.P. Ankerst, C.S. Jiang Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 J Natl Cancer Inst 98 2006 516 521
14. M. Di Maio, C. Gridelli, C. Gallo Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials Lancet Oncol 6 2005 669 677
15. T. Yamanaka, S. Matsumoto, S. Teramukai Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma Br J Cancer 97 2007 37 42
16. D.A. Cameron, C. Massie, G. Kerr Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Br J Cancer 89 2003 1837 1842
17. B.E. Sanchez, J. Munoz, H.Y. Ali Outcome of grade 3 and 4 cytopenia in newly diagnosed glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ) J Clin Oncol 29 suppl 2011 abstract 2018
18. H. Lindman, M. Andersson, P. Edlund A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer J Clin Oncol 29 suppl 2011 abstract 1017
19. P. Edlund, J. Ahlgren, K. Bjerre Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant trial SBG 2000-1 Acta Oncol 50 2011 329 337
20. M.L. Zhu, C.M. Horbinski, M. Garzotto Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res 70 2010 7992 8002
21. G. Sonpavde, G.R. Pond, W.R. Berry The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy Cancer 117 2011 3963 3971
22. J.S. de Bono, H.I. Scher, R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
23. G. Sonpavde, G.R. Pond, W.R. Berry Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy Urol Oncol September 29, 2010 [e-pub ahead of print]
24. U. Gatzemeier, J. von Pawel, I. Vynnychenko First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study Lancet Oncol 12 2011 30 37
25. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
26. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
27. B.I. Rini, D.P. Cohen, D.R. Lu Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
28. M. Colleoni, K. Price, M. Castiglione-Gertsch Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer International Breast Cancer Study Group Eur J Cancer 34 1998 1693 1700
29. M.L. Citron, D.A. Berry, C. Cirrincione Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial: C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431 1439
30. T. Philip, C. Guglielmi, A. Hagenbeek Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 1995 1540 1545
31. P.M. Fracasso, H. Burris III, M.A. Arquette A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing Clin Cancer Res 13 2007 986 993
32. E. Van Cutsem, S. Tejpar, D. Vanbeckevoort Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study J Clin Oncol 30 2012 2861 2868